251 related articles for article (PubMed ID: 30630429)
1. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria.
Bada FO; Okpokoro E; Blok N; Meribole E; Dutt S; Dakum P; Abimiku A; Zwerling A; Kik SV
BMC Infect Dis; 2019 Jan; 19(1):41. PubMed ID: 30630429
[TBL] [Abstract][Full Text] [Related]
2. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
3. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Musa BM; John D; Habib AG; Kuznik A
Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
[TBL] [Abstract][Full Text] [Related]
4. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?
Pooran A; Pieterson E; Davids M; Theron G; Dheda K
PLoS One; 2013; 8(1):e54587. PubMed ID: 23349933
[TBL] [Abstract][Full Text] [Related]
5. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
6. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
7. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
[TBL] [Abstract][Full Text] [Related]
8. Cost of multidrug resistant tuberculosis in Germany-An update.
Diel R; Sotgiu G; Andres S; Hillemann D; Maurer FP
Int J Infect Dis; 2021 Feb; 103():102-109. PubMed ID: 33157286
[TBL] [Abstract][Full Text] [Related]
9. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
10. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
[TBL] [Abstract][Full Text] [Related]
11. Direct costs of pulmonary tuberculosis among patients receiving treatment in Bauchi State, Nigeria.
Umar NA; Abubakar I; Fordham R; Bachmann M
Int J Tuberc Lung Dis; 2012 Jun; 16(6):835-40. PubMed ID: 22613686
[TBL] [Abstract][Full Text] [Related]
12. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
[TBL] [Abstract][Full Text] [Related]
13. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis: cost of illness in Germany.
Diel R; Rutz S; Castell S; Schaberg T
Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
16. Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria.
Bajehson M; Musa BM; Gidado M; Nsa B; Sani U; Habibu AT; Aliyu I; Hussaini T; Yusuf A; Gida Y
PLoS One; 2019; 14(11):e0225165. PubMed ID: 31743358
[TBL] [Abstract][Full Text] [Related]
17. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.
Sinanovic E; Ramma L; Vassall A; Azevedo V; Wilkinson L; Ndjeka N; McCarthy K; Churchyard G; Cox H
Int J Tuberc Lung Dis; 2015 Feb; 19(2):172-8. PubMed ID: 25574915
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
Nam VX; Nhung NV; Hoa NB; Thuy HTT; Phuong NTM; Anh NT; Anh LTN; Trung VQ; Ha TV; Meeyai A; Thavorncharoensap M; Chaikledkaew U
Int J Tuberc Lung Dis; 2018 Aug; 22(8):912-917. PubMed ID: 29991401
[TBL] [Abstract][Full Text] [Related]
19. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
van Rensburg C; Berhanu R; Hirasen K; Evans D; Rosen S; Long L
PLoS One; 2019; 14(6):e0217820. PubMed ID: 31170207
[TBL] [Abstract][Full Text] [Related]
20. Successful expansion of community-based drug-resistant TB care in rural Eswatini - a retrospective cohort study.
Kerschberger B; Telnov A; Yano N; Cox H; Zabsonre I; Kabore SM; Vambe D; Ngwenya S; Rusch B; Tombo ML; Ciglenecki I
Trop Med Int Health; 2019 Oct; 24(10):1243-1258. PubMed ID: 31390108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
